The Journal of Contemporary Dental Practice

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 23 , ISSUE 4 ( April, 2022 ) > List of Articles


Oral Manifestations of Psychotropic Drugs on the Oral Cavity: Observational Study

Priyanka Gandhi, Anupriya Saxena, Keshava Pai, Junaid Ahmed, Ravikiran Ongole

Keywords : Oral manifestations, Psychiatric disorders, Psychotropic drugs

Citation Information : Gandhi P, Saxena A, Pai K, Ahmed J, Ongole R. Oral Manifestations of Psychotropic Drugs on the Oral Cavity: Observational Study. J Contemp Dent Pract 2022; 23 (4):443-446.

DOI: 10.5005/jp-journals-10024-3327

License: CC BY-NC 4.0

Published Online: 11-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Aim: This study aims to detect the prevalence of oral manifestations in patients with psychiatric disorders on psychotropic medications. Materials and methods: A total of 46 patients above the age of 18 years who have been diagnosed with psychiatric illness and under psychotropic medications were included in this study. Thorough case history and oral findings were recorded. Patients with already existing systemic illness and other oral manifestations were excluded from this study. Results: Out of 46 patients, 34 patients presented with oral manifestations such as xerostomia, sialorrhea, geographic tongue, candidiasis, and burning mouth syndrome, secondary to the use of psychotropic medications. The oral manifestations were significantly higher in the patients under antipsychotics (80.0%), selective serotonin reuptake inhibitor (66.7%), antiepileptics (55.6%), antidepressants (44.4%), benzodiazepine (44.4%), and tricyclic antidepressants (13.7%). Conclusion: The commonly used psychotropic medications to treat patients with psychiatric illnesses such as selective serotonin reuptake inhibitor, tricyclic antidepressants, antidepressants, and benzodiazepines exhibited several oral manifestations. However, long-term use of these medications seems to cause oral changes. Clinical significance: Awareness among psychiatrists about oral changes associated with the use of psychotropic medication will assist them to make necessary modifications in the prescriptions. Dental practitioners will be able to recognize these changes early in the course of the condition and provide appropriate treatment.

PDF Share
  1. Dattani S, Ritchie H, Roser M. Mental health. Our world in data. 2018.
  2. Sadock BJ. Psychosocial treatments: general principles. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock's comprehensive textbook of psychiatry. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 3112.
  3. Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. Int J Psychiatry Med 2014;48(3):185–197. DOI: 10.2190/PM.48.3.d.
  4. Robinson HB, Robinson NM. Mentally retarded child. 1976.
  5. Heaton LJ, Swigart K, McNelis G, et al. Oral health in patients taking psychotropic medications: results from a pharmacy-based pilot study. J Am Pharm Assoc 2016;56(4):412–417. DOI: 10.1016/j.japh.2016.03.009.
  6. Peeters F. Dental caries with longterm use of antidepressants. Lancet (London, England) 1995;346(8990):1640. DOI: 10.1016/s0140-6736(95)91980-5.
  7. Peeters FP, DeVries MW, Vissink A. Risks for oral health with the use of antidepressants. Gen Hosp Psychiatry 1998;20(3):150–154. DOI: 10.1016/s0163-8343(98)00017-6.
  8. Lalloo R, Kisely S, Amarasinghe H, et al. Oral health of patients on psychotropic medications: a study of outpatients in Queensland. Austral Psychiatry 2013;21(4):338–342. DOI: 10.1177/1039856213486308.
  9. Keene Jr JJ, Galasko GT, Land MF. Antidepressant use in psychiatry and medicine: importance for dental practice. J Am Dent Assoc 2003;134(1):71–79. DOI: 10.14219/jada.archive.2003.0019.
  10. Alhaffar BA, Abbas G, Latiefeh Y, et al. The oral manifestations of psychiatric disorders. Depression 8:17–40.
  11. Weiden PJ, Citrome L, Alva G, et al. A trial evaluating gradual-or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res 2014;153(1-3):160–168. DOI: 10.1016/j.schres.2013.11.042.
  12. Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995;40(11):983–989. DOI: 10.1016/0003-9969(95)00079-5.
  13. Bardow A, Nyvad B, Nauntofte B. Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ. Arch Oral Biol 2001;46(5):413–423. DOI: 10.1016/s0003-9969(01)00003-6.
  14. Tani H, Uchida H, Suzuki T, et al. Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. BMC Oral Health 2012;12(1):1–6. DOI: 10.1186/1472-6831-12-32.
  15. Hashimoto Y, Uno J, Miwa T, et al. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin Neurosci 2012;66(5):405–410. DOI: 10.1111/j.1440-1819.2012.02376.x.
  16. Moraczewski J, Aedma KK. Tricyclic antidepressants. StatPearls [Internet]; 2020.
  17. Rancans E, Renemane L, Kivite-Urtane A, et al. Prevalence and associated factors of mental disorders in the nationwide primary care population in Latvia: a cross-sectional study. Ann Gen Psychiatry 2020;19(1):25. DOI: 10.1186/s12991-020-00276-5.
  18. Veisani Y, Delpisheh A, Mohamadian F. Prevalence and gender differences in psychiatric disorders and DSM-IV mental disorders: a population-based study. Biomed Res Therapy 2018;5(1):1975–1985. DOI: 10.15419/bmrat.v5i1.412.
  19. Quock RM. Clinical complications in the psychiatric dental patient. Compend Contin Educ Dent 1985;6(5):333. PMID: 3158468.
  20. Kisely S, Quek LH, Pais J, et al. Advanced dental disease in people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2011;199(3):187–193. DOI: 10.1192/bjp.bp.110.081695.
  21. Einhorn OM, Georgiou K, Tompa A. Salivary dysfunction caused by medication usage. Physiol Int 2020;107(2):195–208. DOI: 10.1556/2060.2020.00019.
  22. Raghavan SA, Puttaswamiah RN, Birur PN, et al. Antidepressant-induced burning mouth syndrome: a unique case. Korean J Pain 2014;27(3):294. DOI: 10.3344/kjp.2014.27.3.294.
  23. Ghafoor PF, Rafeeq M, Dubey A. Assessment of oral side effects of Antiepileptic drugs and traumatic oro-facial injuries encountered in Epileptic children. J Int Oral Health: JIOH 2014;6(2):126. PMID: 24876713.
  24. Cockburn N, Pradhan A, Taing MW, et al. Oral health impacts of medications used to treat mental illness. J Affect Disord 2017;223:184–193. DOI: 10.1016/j.jad.2017.07.037.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.